Gastric retained gabapentin dosage form

CAFC
  • US 8,252,332 B2
  • Filed: 03/29/2010
  • Issued: 08/28/2012
  • Est. Priority Date: 10/25/2001
  • Status: Active Grant
First Claim
Patent Images

1. A dosage form, comprising a matrix comprising gabapentin, wherein upon ingestion of the dosage formgabapentin is released from the matrix into the upper gastrointestinal tract over about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration than that provided by an immediate release dosage form comprising an equal amount of gabapentin, andbioavailability of gabapentin is at least 80% of that provided by the immediate release dosage form comprising an equal amount of gabapentin as measured by the area under the plasma concentration-time curve, AUCinf.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×